Home care: a safe and attractive alternative to inpatient administration of intensive chemotherapies.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_7DA3DFC05CBB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Home care: a safe and attractive alternative to inpatient administration of intensive chemotherapies.
Périodique
Supportive Care in Cancer
Auteur(s)
Lüthi F., Fucina N., Divorne N., Santos-Eggimann B., Currat-Zweifel C., Rollier P., Wasserfallen J.B., Ketterer N., Leyvraz S.
ISSN
1433-7339 (Electronic)
ISSN-L
0941-4355
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
20
Numéro
3
Pages
575-581
Langue
anglais
Résumé
OBJECTIVE: The objective of this study was to evaluate feasibility, safety, perception, and costs of home care for the administration of intensive chemotherapies.
METHODS: Patients receiving sequential chemotherapy in an inpatient setting, living within 30 km of the hospital, and having a relative to care for them were offered home care treatment. Chemotherapy was administered by a portable, programmable pump via an implantable catheter. The main endpoints were safety, patient's quality of life [Functional Living Index-Cancer (FLIC)], satisfaction of patients and relatives, and costs.
RESULTS: Two hundred days of home care were analysed, representing a total of 46 treatment cycles of intensive chemotherapy in 17 patients. Two cycles were complicated by technical problems that required hospitalisation for a total of 5 days. Three major medical complications (heart failure, angina pectoris, and major allergic reaction) could be managed at home. Grades 1 and 2 nausea and vomiting occurring in 36% of patients could be treated at home. FLIC scores remained constant throughout the study. All patients rated home care as very satisfactory or satisfactory. Patient benefits of home care included increased comfort and freedom. Relatives acknowledged better tolerance and less asthenia of the patient. Home care resulted in a 53% cost benefit compared to hospital treatment (€420 ± 120/day vs. €896 ± 165/day).
CONCLUSION: Administration of intensive chemotherapy regimens at home was feasible and safe. Quality of life was not affected; satisfaction of patients and relatives was very high. A psychosocial benefit was observed for patients and relatives. Furthermore, a cost-benefit of home care compared to hospital treatment was demonstrated.
Pubmed
Web of science
Création de la notice
25/10/2011 7:55
Dernière modification de la notice
20/08/2019 14:38
Données d'usage